Physician profile

Robert Schleier

Family Medicine · Carolina, PR

NPI 1154493773

$979.26

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$63.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $270.26 2020-2022
Boehringer Ingelheim Pharmaceuticals, INC. $261.60 2019-2024 Jardiance
Sanofi-Aventis U.S. LLC $193.67 2019-2023
Lilly USA, LLC $88.74 2019
Biohaven Pharmaceutical Holding Company Ltd. $75.20 2022
Janssen Pharmaceuticals, INC $44.79 2020-2021
Glaxosmithkline, LLC. $25.00 2020
Merck Sharp & Dohme LLC $20.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Schleier

$979.26

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals Lp

https://glasscript.com/doctor/52530/robert-schleier

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.